ADAR1 Capital Management »

Aclaris Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Aclaris Therapeutics (ACRS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Aclaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aclaris Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aclaris Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $710k 374k 1.90
2024-09-30 $104k 90k 1.15

More positions owned by ADAR1 Capital Management

Abivax Sa Sponsored Ads (ABVX)
Keros Therapeutics (KROS)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Roivant Sciences SHS (ROIV)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Immunovant (IMVT)
89bio (ETNB)
Zai Lab Adr (ZLAB)
Cytokinetics Com New (CYTK)
Septerna (SEPN)
Uniqure Nv SHS (QURE)
Prothena Corp SHS (PRTA)
Bridgebio Pharma (BBIO)
Arbutus Biopharma (ABUS)

View all positions for ADAR1 Capital Management

Top funds holding Aclaris Therapeutics

BML Capital Management
Vivo Capital
Vanguard Group
BlackRock
Adage Capital Partners GP
Rock Springs Capital Management
Decheng Capital
Morgan Stanley
Geode Capital Management
D. E. Shaw & Co
Acadian Asset Management
Marshall Wace
Renaissance Technologies
Palo Alto Investors
Millennium Management

View all funds holding Aclaris Therapeutics